RCM
AZN icon

RB Capital Management’s AstraZeneca AZN Stock Holding History

RB Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
5,389
+9
+0.2% +$1.69K 0.2% 85
2026
Q1 		$1.05M Buy
5,380
+37
+0.7% +$7.13K 0.22% 83
2025
Q4 		$982K Sell
5,343
-203
-4% -$35.6K 0.2% 91
2025
Q3 		$851K Buy
5,546
+278
+5% +$42.1K 0.18% 100
2025
Q2 		$736K Sell
5,268
-301
-5% -$42.2K 0.17% 102
2025
Q1 		$819K Sell
5,569
-408
-7% -$59K 0.19% 95
2024
Q4 		$783K Sell
5,977
-157
-3% -$22K 0.18% 94
2024
Q3 		$956K Sell
6,134
-93
-1% -$15K 0.22% 88
2024
Q2 		$971K Buy
6,227
+117
+2% +$17.6K 0.24% 75
2024
Q1 		$828K Buy
6,110
+1
+0% +$132 0.22% 87
2023
Q4 		$823K Buy
6,109
+7
+0.1% +$910 0.24% 80
2023
Q3 		$826K Buy
6,102
+28
+0.5% +$3.82K 0.26% 74
2023
Q2 		$869K Sell
6,074
-7
-0.1% -$1.03K 0.26% 76
2023
Q1 		$844K Buy
6,081
+57
+0.9% +$7.67K 0.27% 77
2022
Q4 		$817K Buy
6,024
+179
+3% +$22.4K 0.29% 75
2022
Q3 		$641K Buy
5,845
+1,032
+21% +$131K 0.25% 85
2022
Q2 		$636K Buy
4,813
+622
+15% +$81.6K 0.24% 84
2022
Q1 		$556K Buy
4,191
+76
+2% +$9.11K 0.18% 96
2021
Q4 		$479K Buy
4,115
+42
+1% +$4.94K 0.15% 117
2021
Q3 		$489K Buy
4,073
+25
+0.6% +$2.91K 0.18% 101
2021
Q2 		$485K Hold
4,048
– – 0.18% 104
2021
Q1 		$403K Buy
4,048
+272
+7% +$27.3K 0.18% 104
2020
Q4 		$378K Hold
3,776
– – 0.17% 101
2020
Q3 		$412K Buy
3,776
+175
+5% +$19.5K 0.19% 93
2020
Q2 		$381K Buy
3,601
+315
+10% +$32.5K 0.2% 93
2020
Q1 		$288K Buy
3,286
+2,306
+235% +$217K 0.19% 96
2019
Q4 		$281K Sell
980
-1,677
-63% -$158K 0.16% 107
2019
Q3 		$231K Buy
2,657
+195
+8% +$16.9K 0.15% 111
2019
Q2 		$203K Sell
2,462
-101
-4% -$7.92K 0.15% 115
2019
Q1 		$207K Buy
+2,563
New +$202K 0.17% 108

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RB Capital Management's AZN Position: Q2 2026 in Review

RB Capital Management increased its AstraZeneca (AZN) stake by 0.17% in Q2 2026, buying an estimated $1.69K and bringing the position to 5,389 shares worth $1.02M. The position accounts for 0.2% of the portfolio, ranked #85.

RB Capital Management first reported a position in AZN in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.05M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • RB Capital Management held 5,389 shares of AstraZeneca worth $1.02M as of Q2 2026.
  • RB Capital Management bought 9 AstraZeneca shares in Q2 2026, an estimated $1.69K.
  • AstraZeneca made up 0.2% of RB Capital Management's portfolio in Q2 2026, its #85 holding.
  • RB Capital Management first reported a position in AstraZeneca in Q1 2019 and has held it in 30 quarters since.
  • RB Capital Management's AstraZeneca position peaked at $1.05M in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on RB Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.